Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Sep;26(9):1899-907.
doi: 10.1038/leu.2012.121.

EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine

Editorial

EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine

J J M van Dongen et al. Leukemia. 2012 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

JJMvD and AO are the coordinators of the EuroFlow Consortium and are inventors of the EuroFlow patent ‘Methods, reagents and kits for flow cytometric immunophenotyping’ (PCT/NL2010/050332), together with 13 other EuroFlow members. The patent describes the composition of the EuroFlow antibody combinations for diagnosis and classification of hematological malignancies. The patent has been licensed to the companies BD Biosciences and Cytognos for making the antibody combinations commercially available as full-tube combinations in order to speed up the immunostaining process. The patent is collectively owned by the EuroFlow Consortium and the revenues of the patent are exclusively used for EuroFlow Consortium activities, such as for covering (in part) the costs of the Consortium meetings, the EuroFlow Educational Workshops and the purchase of custom-made reagents for collective experiments.

Figures

Figure 1
Figure 1
EuroFlow members attending the first EuroFlow meeting held in Salamanca (April, 2006).
Figure 2
Figure 2
EuroFlow members attending the 19th EuroFlow meeting in Prague (October, 2011).

Similar articles

Cited by

References

    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon; 2008.
    1. Szczepanski T, Orfao A, van der Velden VH, San Miguel JF, van Dongen JJ. Minimal residual disease in leukaemia patients. Lancet Oncol. 2001;2:409–417. doi: 10.1016/S1470-2045(00)00418-6. - DOI - PubMed
    1. Orfao A, Schmitz G, Brando B, Ruiz-Arguelles A, Basso G, Braylan R. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem. 1999;45:1708–1717. - PubMed
    1. Szczepanski T, van der Velden VH, van Dongen JJ. Flow-cytometric immunophenotyping of normal and malignant lymphocytes. Clin Chem Lab Med. 2006;44:775–796. doi: 10.1515/CCLM.2006.146. - DOI - PubMed
    1. Davis BH, Holden JT, Bene MC, Borowitz MJ, Braylan RC, Cornfield D. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry B Clin Cytom. 2007;72(Suppl 1):S5–S13. doi: 10.1002/cyto.b.20365. - DOI - PubMed

Publication types